UltraSight Raises $24M To Expand AI-Guided Echocardiography To Non-Specialist ICU Staff
UltraSight will use the proceeds of its recent $24m Series B2 financing to expand access of cardiac imaging without specialized sonographers into more critical care units and use cases, CEO Davidi Vortman told Medtech Insight.
Medtech Insight - October 5, 2026

Medtronic Scores Regulatory Wins for PAD Balloon, Cardiac Ablation Technology
Medtronic recently announced a couple of regulatory victories across its vascular and cardiac portfolios, including FDA Breakthrough Device designation for an investigational drug-coated balloon for PAD below the knee and FDA clearance and CE Mark approval for an updated cardiac mapping software.
Medtech Insight - October 5, 2026

Vaxcyte VAX-31 Could Be Best-In-Class, Topping Prevnar And Capvaxive
The company announced positive data from a Phase III trial evaluating the safety and immunogenicity of VAX-31, a next-generation 31-valent pneumococcal vaccine.
Scrip - October 5, 2026

A Trio Of Upcoming Phase III Results Could Change Genmab’s Trajectory
The Denmark-headquartered firm could soon become a fully fledged commercial biopharma – but this will hinge on three major trial results due in the fourth quarter.
Scrip - October 5, 2026

Finance Watch: Private Biopharma Companies Pursue All Fundraising Avenues
Private Company Edition: It remains difficult to raise VC cash for early-stage drug development or big manufacturing needs. While Varda raised a $251m series D round for programs based in space, NorthStar entered into a $185m growth financing deal with Hercules Capital.
Scrip - October 5, 2026

Lupin Plans To Cut The Generic Eliquis Line In The US With Differentiated Oral Suspension
Lupin has secured tentative FDA approval for apixaban oral suspension by filing a Paragraph III certification and will target a summer 2027 launch, getting ahead of tablet generics by nearly a year.
Generics Bulletin - October 5, 2026

Who’s Hired? Teva Finds A New Leader For TAPI
Teva has named a new CEO for its TAPI active ingredients business. Meanwhile, Hikma, Sandoz and Stada have announced new hires and a pair of executives have moved from Alvogen and MSN to Accord and Glenmark.
Generics Bulletin - October 5, 2026

Celltrion Offers US First Xolair Biosimilar With Omlyclo Launch
Celltrion has taken pole position in the US omalizumab market by launching Omlyclo, the first and so far only FDA-approved biosimilar rival to Xolair. The launch follows the product’s introduction in Europe last year.
Generics Bulletin - October 5, 2026

FDA’s FY2027 Device Guidance Agenda Prioritizes AI And Surgical Robots, But Delivery Is The Test
CDRH's FY2027 priority list puts AI lifecycle management, predetermined change control plans and surgical robots at the top of its finalization agenda, but with seven of 11 listed guidances published last year and staff still being rebuilt, even A-list timing is a target, not a promise.
Medtech Insight - October 5, 2026

Bayer Boosts Presence In Land Of Opportunity
The German group is planning to invest $2.2bn in a new site in Ohio, building on the more than $7bn it has spent on US pharma R&D and manufacturing over the past five years.
Scrip - October 5, 2026

AI, FDA Pilots, Flexibility: Parexel’s Playbook In A Tough Trial Landscape
Parexel’s COO Rob Goodwin and India chief Sanjay Vyas talk about pairing AI tools to shrink drug development timelines, digital workers for study startup due later this year and business in turbulent times. The CRO is also working to align with the US FDA's Expedited IND Pilot.
Scrip - October 5, 2026

Finland Expands OTC Access But Challenges Remain
Finland has opened applications for companies to sell select non-prescription medicines outside pharmacies from 2027. Haleon is watching the implementation of non-pharmacy sales closely, but tells HBW Insight that “improving access alone is not enough” to expand self-care in the country.
HBW Insight - October 5, 2026

Spain’s Biotech Sector Starts To Come of Age
The director general of the Spanish biotechnology industry association AseBio, Ion Arocena, spoke to Scrip about how Spain the country couldan position itself to be a key global biotech player.
Scrip - October 5, 2026

Over The Counter: Counting Self-Care’s Triple Win, With GSCF’s Greg Perry And Ben Carrick
HBW Insight speaks to GSCF director general Greg Perry and policy committee co-chair Ben Carrick about the federation's 2026 report on the value of self-care, from the welfare gains delivered by OTC medicines to prevention, affordability and faster access through Rx-to-OTC switch.
HBW Insight - October 5, 2026

$2bn IntraBio Buy Sharpens Shionogi’s Rare Disease Pivot
Japanese firm builds its global rare disease portfolio and pipeline with acquisition of US-based IntraBio and lead drug Aqneursa for Niemann-Pick disease Type C.
Scrip - October 5, 2026

Executives On The Move: Abivax Makes C-Suite Changes As Obefazimod Nears FDA Filing
Among other executive moves is Stoke Therapeutics making board changes as the company prepares for potential FDA approval of zorevunersen for Dravet syndrome.
Scrip - October 5, 2026

FDA Consumer Health Advisory: Overton Could Be Industry Ally
What's happening, why it matters and what's next at FDA. This edition explores the confirmation hearing for Commissioner nominee Heidi Overton; the introduction of age restrictions for weight loss products; and teething problems for the roll out of the ACNU switch pathway.
HBW Insight - October 5, 2026

Precision Medicine: A 62-Asset Test Of Whether The Vertex Model Travels Beyond Oncology
Sixty-two products, 36 at late or commercial stage, concentrated in gene therapy and RNA. In Vivo maps non-oncology precision medicine and asks whether emerging clusters in DMD, retinal and CNS disease can replicate the commercial trajectory Vertex proved in cystic fibrosis.
In Vivo - October 5, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: who’s setting the M&A pace this year; Roche’s pipeline reset; wet AMD market shakeup; Merck & Co. pulls I-DXd filing; and Merck withdraws Recarbio from the market.
Scrip - October 5, 2026

US FDA Looking At Ophthalmic Manufacturing With Magnifying Glass
CDER executives note focus on GMP compliance by manufacturers and marketers of eye drops and other ophthalmic products at CHPA Regulation, Scientific & Quality conference.
HBW Insight - October 5, 2026